Catherine Pickering
Professional Overview
Catherine Pickering is an accomplished biopharmaceutical executive with extensive expertise in oncology licensing and business development. As the CEO and Founder of iOnctura SA, she leverages her strategic vision and industry acumen to drive the company's mission of developing innovative cancer therapies.
Experience Summary
Current Role
As the CEO and Founder of iOnctura SA, Catherine is responsible for the overall leadership and strategic direction of the company. Since founding the company in 2017, she has spearheaded the development of a promising pipeline of oncology assets, secured funding, and forged strategic partnerships to accelerate the company's growth and impact.
Career Progression
Prior to founding iOnctura, Catherine held several senior roles at Merck Serono, where she served as the Head of Oncology Licensing and Global Business Development. In this capacity, she was instrumental in identifying and securing licensing opportunities, as well as managing strategic alliances. Earlier in her career, she held business development positions at Antisoma PLC and The Institute of Cancer Research, where she gained valuable experience in the licensing and alliance management domains.
Academic Background
Catherine holds a bachelor's degree in Biochemistry from the University of Cambridge, where she graduated with honors. Her strong academic foundation and specialized knowledge in the life sciences have been instrumental in shaping her successful career in the biopharmaceutical industry.
Areas of Expertise
- Oncology drug development and commercialization
- Licensing and alliance management
- Strategic business development
- Fundraising and investor relations
- Organizational leadership and team management
Professional Impact
Under Catherine's leadership, iOnctura has emerged as a promising player in the oncology space, with a robust pipeline of novel cancer therapies. Her ability to identify and capitalize on strategic opportunities has enabled the company to secure significant funding and forge collaborations with industry-leading partners. Catherine's deep understanding of the oncology landscape and her proven track record of driving innovation have positioned iOnctura as a leading contender in the fight against cancer.
Conclusion
With her extensive experience, strong industry expertise, and visionary leadership, Catherine Pickering is well-positioned to guide iOnctura's continued growth and success. Her unwavering commitment to advancing cancer research and improving patient outcomes has cemented her reputation as a respected and influential figure in the biopharmaceutical industry.
